All In Biotech

Drug Trial Radar · NCT02629549

Intraoperative Imaging of Pituitary Adenomas by OTL

A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma

Last checked: Nov 19, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

33

Actual

Start

Oct 2015

Primary completion

Aug 3, 2018

Study completion Aug 3, 2018

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary end-point of the study is to determine the specificity and sensitivity of OTL38 in identifying pituitary adenomas when excited by an imaging probe. The investigators intend to enroll 50 patients in this study. The study is focusing on patients presenting with suspected pituitary adenomas who are considered to be good surgical candidates.

Conditions

  • Neoplasms
  • Pituitary Neoplasms

Interventions

  • OTL38Drug

    Infusion of OTL38 prior to surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection of OTL38 in tumor tissue.Time frame: 60 months
  2. Evaluate the ability of OTL38 to discern between tumorous tissue and normal, neural tissue.Time frame: 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.